Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Hydra Ink Deal To Develop Novel Ion Channel Antagonists For Pain

This article was originally published in The Pink Sheet Daily

Executive Summary

Collaboration, valued at $195 million, will focus on transient receptor potential ion channel antagonists for pain.

You may also be interested in...



Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates

$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.

Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates

$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.

NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia

Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel